NASDAQ:RZLT Rezolute (RZLT) Stock Price, News & Analysis $6.30 +0.43 (+7.33%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$6.36 +0.06 (+0.87%) As of 07/25/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rezolute Stock (NASDAQ:RZLT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rezolute alerts:Sign Up Key Stats Today's Range$5.81▼$6.3850-Day Range$3.80▼$6.3052-Week Range$2.21▼$6.38Volume1.36 million shsAverage Volume1.60 million shsMarket Capitalization$548.10 millionP/E RatioN/ADividend YieldN/APrice Target$11.83Consensus RatingBuy Company Overview Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Read More Rezolute Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreRZLT MarketRank™: Rezolute scored higher than 53% of companies evaluated by MarketBeat, and ranked 543rd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingRezolute has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRezolute has only been the subject of 2 research reports in the past 90 days.Read more about Rezolute's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Rezolute are expected to decrease in the coming year, from ($0.93) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rezolute is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rezolute is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRezolute has a P/B Ratio of 2.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Rezolute's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.84% of the float of Rezolute has been sold short.Short Interest Ratio / Days to CoverRezolute has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Rezolute has recently increased by 60.70%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRezolute does not currently pay a dividend.Dividend GrowthRezolute does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.84% of the float of Rezolute has been sold short.Short Interest Ratio / Days to CoverRezolute has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Rezolute has recently increased by 60.70%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment0.96 News SentimentRezolute has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Rezolute this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for RZLT on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.MarketBeat Follows3 people have added Rezolute to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Rezolute insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,041,196.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders18.39% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rezolute's insider trading history. Receive RZLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter. Email Address RZLT Stock News HeadlinesBrian Kenneth Roberts Buys 2,500 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockJune 27, 2025 | insidertrades.comRezolute to Participate in the BTIG Virtual Biotechnology ConferenceJuly 22, 2025 | globenewswire.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.July 27 at 2:00 AM | Paradigm Press (Ad)Rezolute Completes Enrollment for Phase 3 sunRIZE StudyJuly 18, 2025 | tipranks.comRezolute files to sell 1.3M shares of common stock for holdersJuly 18, 2025 | msn.comRezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of ...July 10, 2025 | finance.yahoo.comRezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)July 9, 2025 | globenewswire.comRezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77%June 3, 2025 | finance.yahoo.comSee More Headlines RZLT Stock Analysis - Frequently Asked Questions How have RZLT shares performed this year? Rezolute's stock was trading at $4.90 at the beginning of 2025. Since then, RZLT stock has increased by 28.6% and is now trading at $6.30. How were Rezolute's earnings last quarter? Rezolute, Inc. (NASDAQ:RZLT) announced its earnings results on Tuesday, May, 13th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.05. Who are Rezolute's major shareholders? Top institutional investors of Rezolute include Retireful LLC (0.02%). Insiders that own company stock include Young-Jin Kim, Daron Evans, Nevan C Elam, Nevan C Elam, Wladimir Hogenhuis, Wladimir Hogenhuis, Nerissa Kreher and Brian Kenneth Roberts. View institutional ownership trends. How do I buy shares of Rezolute? Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rezolute own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rezolute investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Advanced Micro Devices (AMD), Taiwan Semiconductor Manufacturing (TSM), CrowdStrike (CRWD) and Vanguard S&P 500 ETF (VOO). Company Calendar Last Earnings5/13/2025Today7/26/2025Next Earnings (Estimated)9/18/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RZLT CIK1509261 Webwww.rezolutebio.com Phone(650) 206-4507FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Price Target for Rezolute$11.83 High Price Target$15.00 Low Price Target$9.00 Potential Upside/Downside+87.8%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$68.46 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.09% Return on Assets-63.08% Debt Debt-to-Equity RatioN/A Current Ratio8.43 Quick Ratio8.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.19 per share Price / Book2.88Miscellaneous Outstanding Shares87,000,000Free Float70,997,000Market Cap$548.10 million OptionableOptionable Beta1.03 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:RZLT) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.